Physician profile
Verna Casey
NPI 1609469683
$1,694.99
in general payments reported to CMS, 2019-2025
27 companies · $644 in 2025
The $644 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $415 · 2023: $212 · 2024: $237 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $351.51 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $241.20 | 2022-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $200.88 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Nevro Corp. | $128.06 | 2022 | |
| Abbvie INC. | $98.96 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $75.20 | 2022 | |
| Glaxosmithkline, LLC. | $70.10 | 2023 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $69.29 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.40 | 2025 | Xifaxan |
| Lilly USA, LLC | $48.65 | 2022-2024 | Jardiance, Mounjaro |
| Eisai INC. | $45.22 | 2022-2025 | |
| Viatris Specialty LLC | $33.45 | 2025 | Yupelri |
| Exact Sciences Corporation | $32.70 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $24.83 | 2024 | Yupelri |
| Seqirus USA INC | $22.44 | 2025 | Fluad, Flucelvax |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $21.17 | 2022 | |
| Biosense Webster, INC. | $19.62 | 2022 | |
| Corcept Therapeutics | $19.35 | 2025 | Korlym |
| Cordis US Corp. | $18.81 | 2021 | |
| Neurocrine Biosciences, INC. | $17.53 | 2025 | |
| Cardiva Medical, INC. | $17.51 | 2021 | |
| Cardiovascular Systems INC. | $16.17 | 2022 | |
| Abbott Laboratories | $15.76 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $15.03 | 2025 | Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.14 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $13.90 | 2024 | Rexulti, Abilify Maintena |
| Philips North America LLC | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Verna Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.